Alnylam Pharmaceuticals vs its peers
The 10 largest Pharmaceuticals companies by market value, prices of Nov 20, 2026
Alnylam Pharmaceuticals is the 10th largest of the 10 biggest Pharmaceuticals companies on OQRO by market value, at $19.3B. Its revenue of $3.71B in fiscal 2025 ranks 9th of 10. It keeps 14% of revenue as operating profit, 3rd of 4 (median 19%). Revenue grew 65% on the year before, against a median of +4.7%. At 61.4x its latest annual earnings, the market prices it above its peers (median 24.3x).
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli LillyLLY · FY2025 | $1.27T | $65.2B | +44.7% | +21.6% | 83.0% | — | 31.7% | — | — | 61.4x | 19.4x |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- RPRX66%
- ABBV25%
- ALNY14%
- TEVA12%
Revenue growth, latest year
- ALNY+65.2%
- LLY+44.7%
- ABBV+8.6%
- JNJ+6.0%
Compare Alnylam Pharmaceuticals head to head
Where Alnylam Pharmaceuticals’s revenue comes from and where it goes: Alnylam Pharmaceuticals revenue breakdown. Twenty years of results: Alnylam Pharmaceuticals financial history.
Common questions
Who are Alnylam Pharmaceuticals's competitors?
The largest companies in its industry (Pharmaceuticals) by market value: Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX) and Zoetis (ZTS). They share Alnylam Pharmaceuticals's industry listing; not every one competes with it on every product.
Is Alnylam Pharmaceuticals bigger than Eli Lilly?
No, by market value: Alnylam Pharmaceuticals is worth $19.3B and Eli Lilly $1.27T. By revenue, Alnylam Pharmaceuticals brought in $3.71B in fiscal 2025 and Eli Lilly $65.2B in fiscal 2025.
Where these figures come from
The group is the companies OQRO lists in the same industry as Alnylam Pharmaceuticals (Pharmaceuticals), the largest 9 by market value, plus Alnylam Pharmaceuticals. Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.









